Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study

Article Immunology

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients

Lu Lu et al.

Summary: Immune sera from BNT162b2 and Coronavac recipients showed reduced neutralizing antibody titers against the omicron variant. The presence of the spike R346K mutation did not affect the neutralization susceptibility.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Immunology

Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after infection

Luisa Canto e Castro et al.

Summary: During the COVID-19 pandemic in Portugal, there were three waves of SARS-CoV-2 infection. The study found a significant increase in seroprevalence of SARS-CoV-2 antibodies in the Portuguese population from September 2020 to March 2021, indicating long-lasting infection immunity. Additionally, vaccinated individuals had higher levels of antibodies compared to those previously infected after 3 weeks post-vaccination.

EUROPEAN JOURNAL OF IMMUNOLOGY (2022)

添加到收藏夹

Review Virology

Covid-19 sequelae in working age patients: A systematic review

Gabriele d'Ettorre et al.

Summary: Post-Covid-19 syndrome can significantly impact the health conditions of surviving patients, with a wide range of patients experiencing long-term multiorgan sequelae. Rehabilitation and follow-up in multidisciplinary programs should be considered for working-age patients.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Sue Ann Costa Clemens et al.

Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.

LANCET (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil

Thiago Cerqueira-Silva et al.

Summary: This Brazilian study aimed to estimate the effectiveness of CoronaVac and a booster dose of BNT162b2 vaccine against COVID-19 infection and severe outcomes. The study found that CoronaVac had a 55% effectiveness against infection and 82.1% effectiveness against severe outcomes 14-30 days after the second dose. However, the effectiveness decreased to 34.7% against infection and 72.5% against severe outcomes over 180 days after the second dose. A BNT162b2 booster dose administered 6 months after CoronaVac improved the effectiveness to 92.7% against infection and 97.3% against severe outcomes. Older individuals had lower protection after the second dose but similar protection after the booster.

NATURE MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

Jingxin Li et al.

Summary: The study suggests that additional COVID-19 vaccine doses may be needed for individuals who initially received CoronaVac. Heterologous boosting with Convidecia, a recombinant adenovirus type 5 (AD5)-vectored vaccine, was found to be safe and more immunogenic than homologous boosting with CoronaVac in adults previously vaccinated with CoronaVac.

NATURE MEDICINE (2022)

添加到收藏夹

Article Virology

ViralFlow: A Versatile Automated Workflow for SARS-CoV-2 Genome Assembly, Lineage Assignment, Mutations and Intrahost Variant Detection

Filipe Zimmer Dezordi et al.

Summary: This study developed a workflow for processing and analyzing large-scale SARS-CoV-2 genomic sequencing data. The workflow automates all steps of reference-based genomic analysis and is efficient, versatile, and standardized.

VIRUSES-BASEL (2022)

添加到收藏夹

Article Immunology

Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients

Corine H. GeurtsvanKessel et al.

Summary: This study demonstrates that vaccinated individuals retain T cell immunity to the SARS-CoV-2 Omicron variant, despite low levels of neutralizing antibodies. Booster vaccinations can partially restore cross-neutralization of the Omicron variant.

SCIENCE IMMUNOLOGY (2022)

添加到收藏夹

Article Microbiology

Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil

Felipe Gomes Naveca et al.

Microbiology Spectrum (2022)

添加到收藏夹

Letter Virology

A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine

Lei Yue et al.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Letter Virology

SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen

Ali Umit Keskin et al.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Health Care Sciences & Services

Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study

Thiago Cerqueira-Silva et al.

Summary: This study analyzes the impact of age on the effectiveness of COVID-19 vaccines and finds that vaccine effectiveness decreases with increasing age. Although both vaccines provide some level of protection against infection, hospitalization, and death, they are more effective in individuals under 79 years of age.

LANCET REGIONAL HEALTH-AMERICAS (2022)

添加到收藏夹

Letter Infectious Diseases

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19

Wey Wen Lim et al.

LANCET MICROBE (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu et al.

Summary: The study showed that CoronaVac vaccine is safe and well tolerated in older adults, and is able to induce neutralizing antibody levels. The highest dose of 3 μg of the vaccine can generate neutralizing antibody levels similar to the 6 μg dose, supporting the use of the 3 μg dose CoronaVac in phase 3 trials.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Medicine, General & Internal

Symptoms, complications and management of long COVID: a review

Olalekan Lee Aiyegbusi et al.

Summary: Patients with long COVID experience a wide range of physical and mental symptoms, with common issues including fatigue, shortness of breath, and headaches. Beyond symptoms and complications, they often report impaired quality of life, mental health issues, and employment problems.

JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Mine Durusu Tanriover et al.

Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Alejandro Jara et al.

Summary: A study in Chile involving 10.2 million participants assessed the effectiveness of an inactivated SARS-CoV-2 vaccine developed in China. Fully immunized individuals had vaccine effectiveness of 65.9% for preventing Covid-19 and 87.5% for preventing hospitalization, 90.3% for preventing ICU admission, and 86.3% for preventing death.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study

Otavio Ranzani et al.

Summary: The study evaluates the effectiveness of the CoronaVac vaccine in the elderly population aged >= 70 years in Sao Paulo state, Brazil during widespread circulation of the gamma variant. The vaccine was found to significantly reduce the risk of symptomatic covid-19, hospital admissions, and deaths after completion of the two-dose regimen, but the effectiveness decreases with age among the elderly population.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Immunology

The first 12 months of COVID-19: a timeline of immunological insights

Thiago Carvalho et al.

Summary: The timeline of major scientific discoveries during the first year of the COVID-19 pandemic highlights the collaborative efforts that led to rapid progress in understanding the immune response to SARS-CoV-2. It showcases the unprecedented convergence of research efforts on COVID-19 and identifies gaps in knowledge for future investigations.

NATURE REVIEWS IMMUNOLOGY (2021)

添加到收藏夹

Article Infectious Diseases